成纤维细胞生长因子受体1阳性肺鳞状细胞癌临床病理特征

目的 通过观察成纤维细胞生长因子受体1(FGFR1）蛋白在肺鳞状细胞癌(SCCL)组织中的表达，探讨FGFR1阳性病例的临床病理特征以及免疫组织化学（IHC）方法在筛查肺鳞状细胞癌FGFR1阳性病例中的意义。 方法 应用组织芯片技术制备208例SCCL组织微阵列；应用IHC检测FGFR1蛋白表达，结果与临床病理参数比较分析。 结果 208例SCCL患者中FGFR1阳性13例，阳性率为6.3%。FGFR1阳性组中肿瘤大于5cm患者比例明显高于FGFR1阴性组（P<0.05）；淋巴结转移组FGFR1阳性率较无淋巴结转移组明显增高（9.7% 比 2.9%，P<0.05）； Ⅲ、Ⅳ期患者FGFR1阳性率较Ⅰ、Ⅱ期患者明显增加（13.1% 比 1.6%，P<0.01）。吸烟患者较不吸烟患者FGFR1阳性率差异不明显(P>0.05)，但随吸烟指数的增加，有增高的趋势。结论 FGFR1阳性表达与SCCL患者肿瘤体积较大、淋巴结转移以及临床分期较晚相关；与年龄、性别、肿瘤部位、分化程度及吸烟等无明显相关。

Clinicopathological features of squamous cell carcinoma of the lung expressing fibroblast growth factor receptor 1

Objective To investigate clinicopathological features of patients with squamous cell carcinoma of lung（SCCL) and fibroblastgrowth factor receptor 1（FGFR1）positive expression, and to explore the role of immunohistochemistry (IHC) technology in screening and confirming FGFR1 positive cases. Methods Tissue microarrays were constructed containing 208 SCCL samples. FGFR1 expression was evaluated by IHC staining to analyze its correlation with the clinicopathological characteristics. Results Among 208 patients, the frequency of FGFR1 positive expression was 6.3%. FGFR1 expression was associated with a larger tumor size (>5cm，P<0.05）, and with lymph node metastasis versus no lymph node metastasis（9.7% vs 2.9%，P<0.05）. Positive expression of FGFR1 was higher in patients with stage Ⅲ and Ⅳ than those in stage Ⅰ and Ⅱ（13.1% vs 1.6%，P<0.01）. There was no significant difference between smokers and never smokers (P>0.05). Conclusion FGFR1 expression is associated with larger tumor size、lymph node invasion and clinical stage. FGFR1 expression is not significantly associated with clinicopathologic parameters such as age, sex, tumor location, differentiation and smoking.